Effect of high-dose ulinastatin on the cardiopulmonary bypass-induced inflammatory response in patients undergoing open-heart surgery

[1,2] UTI has recently been considered to be an effective anti-inflammatory agent and has been widely used in clinical settings,[3–5] but the optimal dose has not been defined. [...]we conducted a prospective, randomized, controlled trial involving 60 patients undergoing cardiac surgeries with CPB and investigated the serum levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-8 (IL-8), at different time points in order to evaluate the anti-inflammatory efficacy of high-dose UTI and explore the optimum dose. [...]different routes of UTI administration may restrict its effects. Liu Y, Wang YL, Zou SH, Sun PF, Zhao Q. Effect of high-dose ulinastatin on the cardiopulmonary bypass-induced inflammatory response in patients undergoing open-heart surgery.